Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 2/20 | 0.67 |
| ▸ | BLM | P54132 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.63 |
| ▸ | VCP | P55072 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.63 |
| ▸ | HPRT1 | P00492 | 9/20 | 0.63 |
| ▸ | PNP | P00491 | 5/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | EDNRA | P25101 | 1/20 | 0.59 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | HBB | P68871 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Buciclovir SCHEMBL10918840 | 1.00 | TK1 (0.67) | TK1BLMMEN1ALDH1A1LMNA | |
| Buciclovir SCHEMBL571079 | 1.00 | TK1 (0.67) | TK1BLMMEN1ALDH1A1LMNA | |
| Buciclovir SCHEMBL571385 | 0.95 | HPRT1 (0.67) | TK1BLMMEN1ALDH1A1LMNA | |
| SCHEMBL9663121 | 0.93 | TK1 (0.72) | TK1BLMMEN1ALDH1A1LMNA | |
| Penciclovir SCHEMBL3495 | 0.90 | TK1 (0.70) | TK1BLMMEN1ALDH1A1LMNA | |
| Penciclovir SCHEMBL10414021 | 0.89 | TK1 (0.69) | TK1BLMMEN1ALDH1A1LMNA | |
| Penciclovir SCHEMBL7192792 | 0.89 | TK1 (0.69) | TK1BLMMEN1ALDH1A1LMNA | |
| Penciclovir SCHEMBL583037 | 0.89 | TK1 (0.69) | TK1BLMMEN1ALDH1A1LMNA | |
| SCHEMBL7173165 | 0.88 | TK1 (0.68) | TK1BLMMEN1ALDH1A1LMNA | |
| Buciclovir SCHEMBL11218917 | 0.88 | TK1 (0.56) | TK1BLMMEN1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 600 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2026-05-28 | — | — | US | claimed |
| US-20240139325-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2024-05-02 | — | — | US | claimed |
| EP-4045504-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | Ai-biopharma (FR) | 2022-08-24 | — | — | EP | claimed |
| CN-114901657-A | Antiviral and liver-targeting drugs | 人工智能生物制药公司 | 2022-08-12 | — | — | CN | claimed |
| WO-2021074443-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2021-04-22 | — | — | WO | claimed |
| US-20210094954-A1 | PREPARATION METHODS AND APPLICATIONS OF 3,5-DISUBSTITUTED METHYLPYRAZOLO[1,5-A]PYRIMIDINE-7-HYDROXYLIC SALTS | XU LIFENG (US) | 2021-04-01 | — | — | US | claimed |
| CN-108912055-B | Method for synthesizing antiviral drug cidofovir intermediate and bucyclovir intermediate | 河南师范大学 | 2020-06-30 | — | — | CN | claimed |
| CN-108912055-A | A method of synthesis antiviral agent cidofovir and Buciclovir | 河南师范大学 | 2018-11-30 | — | — | CN | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| EP-2846788-A1 | USE OF COMPOUNDS FOR THE TREATMENT OF PAIN | Akron Molecules AG (AT) | 2015-03-18 | — | — | EP | claimed |
| EP-0577725-A4 | TARGETED DRUG DELIVERY VIA MIXED PHOSPHATE DERIVATIVES | UNIV FLORIDA (US) | 1996-04-17 | — | — | EP | claimed |
| WO-1994026273-A1 | ACYCLOVIR DERIVATIVES FOR TOPICAL USE | HOSTETLER KARL Y (US) | 1994-11-24 | — | — | WO | claimed |
| EP-0577725-A1 | TARGETED DRUG DELIVERY VIA MIXED PHOSPHATE DERIVATIVES | UNIVERSITY OF FLORIDA (US) | 1994-01-12 | — | — | EP | claimed |
| EP-0559744-A1 | COMBINATIONS OF VANILLOID COMPOUNDS AND NUCLEOSIDE ANTIVIRAL COMPOUNDS FOR TREATMENT OF HERPES INFECTIONS | THE PROCTER & GAMBLE COMPANY (US) | 1993-09-15 | — | — | EP | claimed |
| EP-0539493-A4 | TARGETED DRUG DELIVERY VIA PHOSPHONATE DERIVATIVES | — | 1993-06-02 | — | — | EP | claimed |
| EP-0539493-A1 | TARGETED DRUG DELIVERY VIA PHOSPHONATE DERIVATIVES. | BODOR NICHOLAS S (US) | 1993-05-05 | — | — | EP | claimed |
| WO-1992017185-A1 | TARGETED DRUG DELIVERY VIA MIXED PHOSPHATE DERIVATIVES | UNIVERSITY OF FLORIDA (US) | 1992-10-15 | — | — | WO | claimed |
| WO-1992009287-A1 | COMBINATIONS OF VANILLOID COMPOUNDS AND NUCLEOSIDE ANTIVIRAL COMPOUNDS FOR TREATMENT OF HERPES INFECTIONS | THE PROCTER & GAMBLE COMPANY (US) | 1992-06-11 | — | — | WO | claimed |
| WO-1992000988-A1 | TARGETED DRUG DELIVERY VIA PHOSPHONATE DERIVATIVES | BODOR NICHOLAS S (US) | 1992-01-23 | — | — | WO | claimed |
| US-4495190-A | VIRICIDES; ANTITUMOR AND ANTICARCINOGENIC AGENTS | ASTRA LAKEMEDEL AKTIEBOLAG (SE) | 1985-01-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | HAVCR2, NR1H4, NR1H3 | TK1 98/4885BLM 4147/4885MEN1 3514/4885 |
| US-20210094954-A1 | PREPARATION METHODS AND APPLICATIONS OF 3,5-DISUBSTITUTED METHYLPYRAZOLO[1,5-A]PYRIMIDINE-7-HYDROXYLIC SALTS | DHPS, NUDT1, DPYD | TK1 40/4885BLM 3605/4885MEN1 522/4885 |
| US-20240139325-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | SLC10A1, HAVCR2, HDGF | TK1 37/4885BLM 3381/4885MEN1 3496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.